Emphasizing the evidence-based nature of medicine, Nathan Goodyear, MD, explained that integrative oncology uses many of the same parameters and key clinical thresholds among patients undergoing treatment for a diagnosis of cancer that his conventional oncologist colleagues use.

In this episode of Oncology on the Go, Goodyear, an integrative medicine physician at the Williams Cancer Institute, discussed key clinical efficacy and safety thresholds that integrative oncologists use for flagship integrative therapies, emerging localized and combinatory immunotherapy options in this clinical landscape, and a focus on reestablishing trust through patient-doctor relationships.

Regarding clinical thresholds, he explained that integrative care uses guidelines such as the CTCAE to follow adverse effects (AEs). RECIST criteria are also employed to ascertain clinical outcomes and utilize imaging to gauge responses in a way that is not arbitrary but translatable.

Next, Goodyear discussed combinatory regimens with immunotherapy backbones, such as pulsed electric fields (PEF) with intratumoral immunotherapy, as well as anti-CD40/CpG immunotherapies, to help generate an intratumoral response prior to resection, particularly in “immune desert” tumors. He noted how these strategies may also mitigate the possibility of postoperative recurrence.

Finally, he touched upon the evolving role of doctors as collaborators with their patients as opposed to a paternalistic and authoritative role over the course of their treatment. Driven by growing demands for a greater desire to preserve quality of life during care, Goodyear explained that his institution aims to “innovate, elevate, and empower” by bringing emergent innovative strategies to patients, elevating their immune system through immune responses, and empowering patients to undergo the healing process in tandem with a reduction of AEs.

Goodyear concluded by reiterating the importance of patient-centric care, particularly as it pertains to the restoration of trust in medicine, as well as a return to a doctor’s intended rule as a healer.

For more expert-level discussions across the oncology paradigm, check out the newest podcast series on CancerNetwork®, RadOnc on the Run. Join host and ONCOLOGY® editor-at-large Brandon Mancini, MD, MBA, FACRO, as he speaks with colleagues about the latest advancements and hottest research in the radiation oncology space.